When PSA levels rise after initial treatments, patients face the difficult realization that their cancer is likely a chronic condition to be managed, not a disease to be cured. This existential moment requires a fundamental shift in their approach and expectations for the rest of their lives.
For patients who meet EMBARK criteria but also show oligometastatic disease on PSMA PET, clinicians are adopting a pragmatic approach. They combine the evidence-backed systemic hormone therapy from the trial with targeted radiation of metastatic sites, aiming to prolong the time until therapy needs to be restarted.
The prospect of lifelong hormone therapy can be mentally crushing for patients. In contrast, a fixed, nine-month treatment plan with a clear end date provides a manageable timeline. This psychological relief is a significant, non-clinical factor that improves patient quality of life and their ability to cope with treatment.
Though EMBARK trial patients were negative on conventional imaging, an analysis suggests over 80% had PSMA PET-detectable disease. This reframes the landmark study, suggesting its findings may apply more to treating low-volume metastatic disease intermittently rather than purely biochemical recurrence.
A PSA doubling time of less than three months acts as a surrogate marker for death from prostate cancer. This powerful heuristic doesn't predict exact lifespan, but it signifies that the cancer's mortality risk has surpassed all other potential causes of death for that individual, signaling extreme high risk.